Stock Events

Stock Events

Acadia Pharmaceuticals 

$26.2
0
+$0+0% Today

Statistics

Day High
26.2
Day Low
26.2
52W High
-
52W Low
-
Volume
3
Avg. Volume
-
Mkt Cap
4.43B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2MarExpected
Q3 2025
Next
0.14
0.23
0.33
0.42
Expected EPS
0.13641
Actual EPS
N/A

Financials

23.64%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
1.92BRevenue
452.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACAD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops drugs that directly compete in the neurological and psychiatric drug markets.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company offers a range of products that target the central nervous system, making it a direct competitor in the psychiatric and neurological drug markets.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has a strong portfolio in neuroscience, competing in the development and marketing of drugs for psychiatric and neurological disorders.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diversified portfolio that includes treatments for neurological conditions, directly competing with Acadia's offerings.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. focuses on neurology, developing treatments for diseases like multiple sclerosis and Alzheimer's, areas that overlap with Acadia's focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited has a broad portfolio that includes CNS (central nervous system) drugs, making it a competitor in the neurological and psychiatric medication market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a growing interest in neuroscience, including R&D in Parkinson's and Alzheimer's, which competes with Acadia's focus areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the development of drugs that target neurological disorders, positioning it as a competitor in the same therapeutic area as Acadia.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc has a focus on central nervous system (CNS) disorders, including schizophrenia and depression, directly competing with some of Acadia's key products.

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Stephen R. Davis J.D.
Employees
510
Country
United States
ISIN
US0042251084

Listings

LSE
GB
0A4W.LSE
XNAS
US
ACAD
F
DE
DR6.F
BOATS
BOATS
ACAD.BOATS

0 Comments

Share your thoughts

FAQ

What is Acadia Pharmaceuticals stock price today?▼
The current price of ACAD.BOATS is $26.2 USD — it has increased by +0% in the past 24 hours. Watch Acadia Pharmaceuticals stock price performance more closely on the chart.
What is Acadia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Acadia Pharmaceuticals stocks are traded under the ticker ACAD.BOATS.
What is Acadia Pharmaceuticals market cap?▼
Today Acadia Pharmaceuticals has the market capitalization of 4.43B
When is the next Acadia Pharmaceuticals earnings date?▼
Acadia Pharmaceuticals is going to release the next earnings report on March 02, 2026.
What were Acadia Pharmaceuticals earnings last quarter?▼
ACAD.BOATS earnings for the last quarter are 0.42 USD per share, whereas the estimation was 0.17 USD resulting in a +142.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Acadia Pharmaceuticals revenue for the last year?▼
Acadia Pharmaceuticals revenue for the last year amounts to 1.92B USD.
What is Acadia Pharmaceuticals net income for the last year?▼
ACAD.BOATS net income for the last year is 452.9M USD.
How many employees does Acadia Pharmaceuticals have?▼
As of February 02, 2026, the company has 510 employees.
In which sector is Acadia Pharmaceuticals located?▼
Acadia Pharmaceuticals operates in the Other sector.
When did Acadia Pharmaceuticals complete a stock split?▼
Acadia Pharmaceuticals has not had any recent stock splits.
Where is Acadia Pharmaceuticals headquartered?▼
Acadia Pharmaceuticals is headquartered in San Diego, United States.